ResearchMoz

Breast Cancer Market Research Reports & Industry Analysis

Studies claim that breast cancer is the second most common type of cancer found in women, and most of the cases occur in women aged over 50 years. 

Breast cancer is a type of cancer that is formed in the breast cells. It begins in a cell and multiplies and divides at an uncontrolled rate. It usually starts off in the inner lining of the milk ducts or the lobules that supply them with milk. A small clump of cancer cells are just impossible to be felt for stating it as breast cancer, and hence, the best option to sense them is at its earliest stages that usually have no symptoms. If breast cancer is diagnosed and treated at an early stage, there is a better chance of a cure; however, if it advances to further stages, the treatment chances are less curable. 

The most ideal symptom of breast cancer is a lump that is found in the armpit or breast. One can also look out for other symptoms such as clear or bloody nipple discharge, pain in the nipple, scaly or pitted skin on the nipple, and inverted or retracted nipple. However, studies say the reasons for breast cancer are not focused on one disease, but it is a complex group of diseases that occurs unanimously due to many reasons. Some statistical studies even say that breast cancer is due to the growing ecological and body burden pressures that set the connection between the environmental factors and breast cancer. 

Despite increased access to medical advancements and better treatments for women, 40,000 women become victims and die of this disease every year. In every two minutes, a woman is diagnosed with breast cancer. ResearchMoz pharmaceutical and healthcare market research reports serves detailed analysis, factors, and competitive analysis of all these factors, and more. Our effective team of research analysts’ compiles the breast cancer reports using the most comprehensive information and sources it to the customers from industry best reputable publishers. 

Browse through the expansive section on ResearchMoz for more information and insights into this industry.
Breast Cancer

Browse reports in Breast Cancer

Displaying 1 to 24 (of 24 records)
Global Breast Cancer Market Report: 2014 Edition
Aug 2014   |   By - Koncept Analytics
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Breast cancer knows no boundaries be it age, gender, socioeconomic status or geographic location. The most common risk factors for breast cancer are being female and growing older. In the past few years, the cases of breast cancer have increased tremendously in regions like the US...
$800
Breast Cancer Market Report: 2013 Edition
Jun 2013   |   By - Koncept Analytics
Riding on the back of evolving technological environment, the global healthcare and pharmaceutical industry is now surmounting new acmes. The growth of the respective sector is further filliped by the increasing number of health related issues surfacing on account of changing lifestyle and incessantly evolving surroundings.  To cater to the necessity of better healthcare...
$800
US Market Changes in the Treatment of Advanced Breast Cancer
Sep 2012   |   By - Assessment Group
A survey with unfolding patient case scenarios was presented to 180 U.S. oncologists who manage patients with metastatic breast cancer for their open-ended responses. In each case, oncologists were asked to respond to questions concerning their choices of treatment regimens, factors that influenced their decisions, barriers to optimal patient treatment and confidence in treatment and...
$2900
Avastin (Breast Cancer) Analysis and Forecasts to 2020
Dec 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Avastin (Breast Cancer) Analysis and Forecasts to 2020 provides Avastin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer...
$2000
Taxol (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Taxol (Breast Cancer) Analysis and Forecasts to 2020 provides Taxol sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on...
$2000
Taxotere (Breast Cancer) Analysis and Forecats to 2017
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Taxotere (Breast Cancer) Analysis and Forecasts to 2017 provides Taxotere sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2017). The report also includes information on...
$2000
Femara (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Femara (Breast Cancer) Analysis and Forecasts to 2020 provides Femara sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer...
$2000
Herceptin (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Herceptin (Breast Cancer) Analysis and Forecasts to 2020 provides Herceptin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast...
$2000
Omnitarg (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Omnitarg (Breast Cancer) Analysis and Forecasts to 2020 provides Omnitarg sales estimates for US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer...
$2000
Trastuzumab-DM1 (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Trastuzumab-DM1 (Breast Cancer) Analysis and Forecasts to 2020 provides Trastuzumab-DM1 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2020). The report also includes...
$2000
Gemzar (Breast Cancer) Analysis and Forecasts to 2015
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Gemzar (Breast Cancer) Analysis and Forecasts to 2015 provides Gemzar sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2003-2015). The report also includes information on Breast...
$2000
Afinitor (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Afinitor (Breast Cancer) Analysis and Forecasts to 2020 provides Afinitor sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on...
$2000
Arimidex (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Arimidex (Breast cancer) - Analysis and Forecasts to 2020 provides Arimidex sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer...
$2000
Aromasin (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Aromasin (Breast cancer) - Analysis and Forecasts to 2020 provides Aromasin sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the estimate period (2002-2020). The report also includes information on Breast Cancer...
$2000
Faslodex (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Faslodex (Breast cancer) - Analysis and Forecasts to 2020 provides Faslodex sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the estimate period (2002-2020). The report also includes information on Breast...
$2000
Neratinib (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Neratinib (Breast cancer) - Analysis and Forecasts to 2020 provides Neratinib sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Breast Cancer...
$2000
Nolvadex (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Nolvadex (Breast cancer) - Analysis and Forecasts to 2020 provides Nolvadex sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forcast period . The report also includes information on Breast Cancer market....
$2000
Tykerb (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Tykerb (Breast cancer) - Analysis and Forecasts to 2020 provides Tykerb sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer...
$2000
Xeloda (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Xeloda (Breast cancer) - Analysis and Forecasts to 2020 provides Xeloda sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer...
$2000
Zoladex (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Zoladex (Breast cancer) - Analysis and Forecasts to 2020 provides Zoladex sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer...
$2000
Abraxane (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Abraxane (Breast cancer) - Analysis and Forecasts to 2020 provides Abraxane sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2005-2017). The report also includes information on...
$2000
Ellence (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Ellence (Breast cancer) - Analysis and Forecasts to 2020 provides Ellence sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2014). The report also includes information on...
$2000
Halaven (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Halaven (Breast cancer) - Analysis and Forecasts to 2020 provides Halaven sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2011-2020). The report also includes information on Breast Cancer...
$2000
Breast Cancer Market Report: 2011 Edition
Jun 2011   |   By - Koncept Analytics
Breast cancer is one of the most common types of cancer after lung cancer and the second leading cause of death in women. Globally, more than one million women are diagnosed with breast cancer annually. Breast cancer is mainly found in women compared to men. Though women of all ages are at risk of developing breast cancer, older woman have greater chances of developing it. The incidence rates...
$800
 
Displaying 1 to 24 (of 24 records)

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com

Popular Publishers

Transparency Market Research
ICD Research
Technavio
 
GBI Research
Winter Green Research
GlobalData